These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 33537531)

  • 1. Tapering thrombopoietin receptor agonists in primary immune thrombocytopenia: Expert consensus based on the RAND/UCLA modified Delphi panel method.
    Cuker A; Despotovic JM; Grace RF; Kruse C; Lambert MP; Liebman HA; Lyons RM; McCrae KR; Pullarkat V; Wasser JS; Beenhouwer D; Gibbs SN; Yermilov I; Broder MS
    Res Pract Thromb Haemost; 2021 Jan; 5(1):69-80. PubMed ID: 33537531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. European Delphi panel to build consensus on tapering and discontinuing thrombopoietin receptor agonists in immune thrombocytopenia.
    Barlassina A; González-López TJ; Cooper N; Zaja F
    Platelets; 2023 Dec; 34(1):2170999. PubMed ID: 36803535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Second-line administration of thrombopoietin receptor agonists in immune thrombocytopenia: Italian Delphi-based consensus recommendations.
    Carpenedo M; Baldacci E; Baratè C; Borchiellini A; Buccisano F; Calvaruso G; Chiurazzi F; Fattizzo B; Giuffrida G; Rossi E; Palandri F; Scalzulli PR; Siragusa SM; Vitucci A; Zaja F
    Ther Adv Hematol; 2021; 12():20406207211048361. PubMed ID: 34646432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tapering and Discontinuation of Thrombopoietin Receptor Agonist Therapy in Patients with Immune Thrombocytopenia: Results from a Modified Delphi Panel.
    Cooper N; Hill QA; Grainger J; Westwood JP; Bradbury C; Provan D; Thachil J; Ramscar N; Roy A
    Acta Haematol; 2021; 144(4):418-426. PubMed ID: 33789275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of thrombopoietin receptor agonists in adults with immune thrombocytopenia: a systematic review and Central European expert consensus.
    Pulanić D; Bátorová A; Bodó I; Červinek L; Ionita I; Lissitchkov T; Melikyan A; Podolak-Dawidziak M
    Ann Hematol; 2023 Apr; 102(4):715-727. PubMed ID: 36826482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complement activation negatively affects the platelet response to thrombopoietin receptor agonists in patients with immune thrombocytopenia: a prospective cohort study.
    Åkesson A; Bussel JB; Martin M; Blom AM; Klintman J; Ghanima W; Zetterberg E; Garabet L
    Platelets; 2023 Dec; 34(1):2159019. PubMed ID: 36636835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment-free remission after thrombopoietin receptor agonist discontinuation in patients with newly diagnosed immune thrombocytopenia: an observational retrospective analysis in real-world clinical practice.
    Iino M; Sakamoto Y; Sato T
    Int J Hematol; 2020 Aug; 112(2):159-168. PubMed ID: 32476083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tapering and discontinuation of thrombopoietin receptor agonists in immune thrombocytopenia: Real-world recommendations.
    Zaja F; Carpenedo M; Baratè C; Borchiellini A; Chiurazzi F; Finazzi G; Lucchesi A; Palandri F; Ricco A; Santoro C; Scalzulli PR
    Blood Rev; 2020 May; 41():100647. PubMed ID: 31818701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombopoietin receptor agonist (TPO-RA) treatment raises platelet counts and reduces anti-platelet antibody levels in mice with immune thrombocytopenia (ITP).
    Kapur R; Aslam R; Speck ER; Rebetz JM; Semple JW
    Platelets; 2020; 31(3):399-402. PubMed ID: 31146647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained remission of chronic immune thrombocytopenia after discontinuation of treatment with thrombopoietin-receptor agonists in adults.
    Červinek L; Mayer J; Doubek M
    Int J Hematol; 2015 Jul; 102(1):7-11. PubMed ID: 25833724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolonged response after TPO-RA discontinuation in primary ITP: results of a prospective multicenter study.
    Guillet S; Crickx E; Azzaoui I; Chappert P; Boutin E; Viallard JF; Rivière E; Gobert D; Galicier L; Malphettes M; Cheze S; Lefrere F; Audia S; Bonnotte B; Lambotte O; Noel N; Fain O; Moulis G; Hamidou M; Gerfaud-Valentin M; Marolleau JP; Terriou L; Martis N; Morin AS; Perlat A; Le Gallou T; Roy-Peaud F; Robbins A; Lega JC; Puyade M; Comont T; Limal N; Languille L; Zarrour A; Luka M; Menager M; Belmondo T; Hue S; Canoui-Poitrine F; Michel M; Godeau B; Mahévas M
    Blood; 2023 Jun; 141(23):2867-2877. PubMed ID: 36893453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment patterns of thrombopoietin receptor agonists among adults with primary immune thrombocytopenia: A Korean nationwide population-based study.
    Lee JY; Lee JH; Kim SA; Suh KJ; Kim JW; Kim SH; Lee JO; Kim JW; Kim YJ; Lee KW; Kim JH; Lee JS; Bang SM
    Thromb Res; 2022 May; 213():114-118. PubMed ID: 35334441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eltrombopag modulates the phenotypic evolution and potential immunomodulatory roles of monocytes/macrophages in immune thrombocytopenia.
    Yang F; Zong H; Li F; Luo S; Zhang X; Xu Y; Zhang X
    Platelets; 2023 Dec; 34(1):2135694. PubMed ID: 36281771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased microvesicle-associated thrombin generation in patients with immune thrombocytopenia after initiation of thrombopoietin receptor agonists.
    Garabet L; Ghanima W; Hellum M; Sandset PM; Bussel JB; Tran H; Henriksson CE
    Platelets; 2020; 31(3):322-328. PubMed ID: 31280643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thrombopoietin receptor agonists and rituximab for treatment of pediatric immune thrombocytopenia: A systematic review and meta-analysis of prospective clinical trials.
    Ayad N; Grace RF; Al-Samkari H
    Pediatr Blood Cancer; 2022 Mar; 69(3):e29447. PubMed ID: 34962697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombopoietin receptor agonists for prevention and treatment of chemotherapy-induced thrombocytopenia in patients with solid tumours.
    Zhang X; Chuai Y; Nie W; Wang A; Dai G
    Cochrane Database Syst Rev; 2017 Nov; 11(11):CD012035. PubMed ID: 29178132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment patterns and outcomes of second-line rituximab and thrombopoietin receptor agonists in adult immune thrombocytopenia: A Canadian retrospective cohort study.
    Podstawka J; Wall E; Bolster L; Patterson JM; Goodyear MD; Rydz N; Sun HL
    Thromb Res; 2022 Dec; 220():5-11. PubMed ID: 36257098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An updated evaluation of avatrombopag for the treatment of chronic immune thrombocytopenia.
    Song AB; Al-Samkari H
    Expert Rev Clin Immunol; 2022 Aug; 18(8):783-791. PubMed ID: 35793401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world impact of primary immune thrombocytopenia and treatment with thrombopoietin receptor agonists on quality of life based on patient-reported experience: Results from a questionnaire conducted in Switzerland, Austria, and Belgium.
    Rovó A; Cantoni N; Samii K; Rüfer A; Koenen G; Ivic S; Cavanna D; Benz R
    PLoS One; 2022; 17(4):e0267342. PubMed ID: 35446925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thrombopoietin receptor agonist discontinuation rates and reasons among patients with immune thrombocytopenia: a study of administrative claims linked with medical chart review.
    Cuker A; Lal L; Roy A; Elliott C; Carlyle M; Martin C; Haenig J; Viana R
    Ann Hematol; 2022 Sep; 101(9):1915-1924. PubMed ID: 35849155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.